Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609574 | 1.00 | BACE1 (0.40) | BACE1CYP2D6ADRB2ADRB1NFKB1 | |
| SCHEMBL4609571 | 1.00 | BACE1 (0.40) | BACE1CYP2D6ADRB2ADRB1NFKB1 | |
| SCHEMBL9766295 | 0.82 | BACE1 (0.42) | BACE1CYP2D6ADRB2ADRB1NFKB1 | |
| SCHEMBL13577115 | 0.81 | BACE1 (0.43) | BACE1CYP2D6ADRB2ADRB1NFKB1 | |
| SCHEMBL20417162 | 0.77 | ADRB1 (0.33) | BACE1ADRB1 | |
| SCHEMBL14502747 | 0.77 | BACE1 (0.35) | BACE1CYP2D6HIF1ACASR | |
| SCHEMBL4609334 | 0.77 | BACE1 (0.35) | BACE1CYP2D6HIF1ACASR | |
| SCHEMBL14502746 | 0.77 | BACE1 (0.35) | BACE1CYP2D6HIF1ACASR | |
| SCHEMBL4609336 | 0.77 | BACE1 (0.35) | BACE1CYP2D6HIF1ACASR | |
| SCHEMBL1600845 | 0.76 | PDE2A (0.47) | CYP2D6ADRB2PDE2ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308436-B1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-7211685-B2 | Calcium receptor antagonists | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-6916956-B2 | Calcium receptor antagonist | JAPAN TOBACCO, INC. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050107448-A1 | Calcium receptor antagonists | JAPAN TABACCO INC. | 2005-05-19 | — | — | US | disclosed |
| US-20040006130-A1 | Calcium receptor antagonist | JAPAN TOBACCO INC (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1308436-A1 | CALCIUM RECEPTOR ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107448-A1 | Calcium receptor antagonists | CASR, CALCR, CALCRL | BACE1 1170/4885CYP2D6 497/4885ADRB2 514/4885 |
| US-20040006130-A1 | Calcium receptor antagonist | CALCRL, CASR, CALCR | BACE1 1227/4885CYP2D6 373/4885ADRB2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.